White Papers
The benefits of 5,000L singleuse bioreactors for biologics manufacturing
The market for complex biologics including monoclonal antibodies, bispecific antibodies and fusion molecules is growing at a rapid pace.
European regulatory landscape: Demystifying new Qualified Person (QP) requirements for Supplying medicine in the EU and UK
Qualified persons (QPs) play an essential role in the European clinical trial supply chain.
EU Clinical Trial Regulation 2022
Thermo Fisher Scientific's group of experts delve into the impact of the latest EU Clinical Trial Regulation on pharmaceutical companies and their research and business associates. They examine critical considerations and potential pitfalls in the context of European Union member countries, as well as European Economic Area (EEA) countries.
Technology transfers: Best practices for optimizing success and mitigating risk
Whether changing manufacturing sites for scale up or passing from development to manufacturing, technology transfers are a critical process every drug must go through on its route to market.
Unveiling the Future of Pharma: The Nexus Between Patients and Big Pharma
Discover the groundbreaking insights from the CPHI Trend Report on the pivotal connection between patients and the pharmaceutical industry.
Transforming Patient Care: Elevating Cell and Gene Therapy Journeys Through Integrated CRO/CDMO Collaboration
Discover the power of cell and gene therapies in our exclusive whitepaper focusing on optimizing patient journeys through integrated CRO/CDMO partnerships.
Label-free Analysis – The End of End-Point Assays
Drug development is predicated on the identification of therapeutic targets, typically proteins or nucleic acids, that play a causal role in a disease and are ‘druggable’, i.e., amenable to pharmacological action by the drug.
Al-Enabled Route Scouting Service Technical Brief
Small molecule active pharmaceutical ingredients (APls) are becoming more molecularly complex, resulting in formidable challenges for small and emerging biotechs.
Revolutionize Drug Development with AI/ML
Poor solubility remains one of the most significant challenges in drug development, affecting over 70% of molecules and hindering their path to clinical trials.
Accelerate Drug Development with In Silico Modeling
The path to successful drug development is filled with challenges, from managing complex molecules to ensuring bioavailability and regulatory compliance.
